# Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

> **NCT02027961** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 68 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02027961
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-20
- **Primary completion:** 2018-04-24
- **Final completion:** 2018-04-24
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027961, "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02027961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*